Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A

Alpha memo: Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A

Hypothesis-level alpha signal; not clinical advice.

Core signal

Receipt 10.1111/acel.13039 and receipt 10.1093/geroni/igy023.2009 are both reports from the MASTERS trial in older adults (65+) randomized to metformin versus placebo across 14 weeks of progressive resistance exercise training (PRT). Despite differing abstract framings, the reported lean-mass and thigh-muscle endpoints move in the same direction: the placebo arm gains more lean body mass, thigh muscle mass, thigh muscle area, and normal-density thigh muscle than the metformin arm. Strength is reported separately in receipt 10.1111/acel.13039 as a trend toward blunted gain with metformin. Net call: comparator-favored on hypertrophy endpoints; do not treat as a metformin efficacy win.

The 2+2=5 angle

Receipt 10.1111/acel.13039 states the trial hypothesized metformin would augment the muscle response to PRT; receipt 10.1093/geroni/igy023.2009 frames the same MASTERS study with the identical augment-strength hypothesis and title framing. Observed DXA, CT, and RNAseq measures in both receipts undercut that augmentation hypothesis at the lean-mass and thigh-muscle endpoints. The 2+2=5 is the title-versus-data gap inside one trial, not a cross-trial contradiction. Because both receipts measure the same endpoint family, the contrast is direct, and the signal reads comparator-favored / mixed.

Why this could matter

• The rationale was anti-inflammatory augmentation of hypertrophy; the in-trial muscle gene-expression readouts in receipt 10.1093/geroni/igy023.2009 are flagged as potentially blunted, so the hypothesized mediator is also pointing the wrong way (hypothesis, not confirmed endpoint).
• A pragmatic implication, scoped to the trial: in healthy adults aged 65+ on 1,700 mg/day metformin, co-administered metformin during a 14-week PRT block is associated with attenuated lean-mass and thigh-muscle gains versus placebo, with a directional trend on strength. Receipt 10.3410/f.736671936.793569870 is a Faculty Opinions recommendation of receipt 10.1111/acel.13039, reinforcing this same direction; it is replication context, not a new effect.

What would break the idea

A pre-specified, metformin-status-stratified PRT trial in older adults (chronic users versus naïve) with harmonized DXA and CT endpoints, plus an inflammation-mechanistic co-primary, would resolve whether the attenuation is a drug-effect boundary or a population/comorbidity artifact. Receipts do not supply that design.

Claim ledger

• 10.1111/acel.13039 — role=evidence; design=randomized_trial; population=human; outcome=unspecified; direction=negative; support=direct/high; quote="placebo gained more lean body mass (p = .003) and thigh muscle mass (p < .001) than metformin … trend for blunted strength gai …"
• 10.1093/geroni/igy023.2009 — role=evidence; design=randomized_trial; population=human; outcome=unspecified; direction=positive; support=direct/high; quote="lean mass increased overall (P < 0.0001), with the metformin group gaining significantly less lean mass than the placebo group (P < 0.01) …"
• 10.3410/f.736671936.793569870 — role=replication; design=randomized_trial; population=human; outcome=unspecified; direction=negative; support=direct/high; quote="Faculty Opinions recommendation of Metformin blunts muscle hypertrophy in response to progressive resistance exercise training …"

Receipts

• 10.1111/acel.13039 — Aging Cell, 2019 — randomized, double-blind, placebo-controlled, multicenter MASTERS trial; 1,700 mg/day metformin vs placebo plus 14 weeks supervised PRT in adults ≥65.
• 10.1093/geroni/igy023.2009 — 2018 — MASTERS trial; metformin vs placebo plus 14 weeks resistance training; per-protocol analysis at two sites.
• 10.3410/f.736671936.793569870 — 2020 — Faculty Opinions recommendation of receipt 10.1111/acel.13039.

Safety note

Receipts describe feasibility-scale, randomized, double-blind, placebo-controlled trial evidence in adults aged 65+; no clinical advice is offered.